Cost-Effectiveness Of Daclizumab Versus Fingolimod In The Treatment Of Patients With Relapsing-Remitting Multiple Sclerosis In Norway
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.503
https://www.valueinhealthjournal.com/article/S1098-3015(16)31870-8/fulltext
Title :
Cost-Effectiveness Of Daclizumab Versus Fingolimod In The Treatment Of Patients With Relapsing-Remitting Multiple Sclerosis In Norway
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)31870-8&doi=10.1016/j.jval.2016.09.503
First page :
A433
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
471